DBV Technologies
USUSDDBV Technologies (US:DBVTF) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 3. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
O firmie
- Strona
- dbv-technologies.com
- Relacje inwestorskie
- dbv-technologies.com/investor-overview/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siedziba
- CHATILLON, France
- Prezes
- Daniel Tassé
- Pracownicy
- 170
- Założona
- 2002
- Akcje w obrocie
- 296.06 mln na 2026-07-16
- Free float
- 34.94 mln
- Kapitalizacja rynkowa
- 731.56 mln USD
- Insiderzy
- 0%
- Inwestorzy instytucjonalni
- 41.66%
- Branża (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma prawna
- K65D
- ISIN
- FR0010417345
- LEI
- 969500PVBQFWQKVDMD80
- FCF
- −171 mln USD
- Dług
- 510 tys. USDgotówka netto
- Zyski i FCF — za 12 miesięcy do 30.06.2026 roku (najnowszy raport firmy).
Opis
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Wiadomości w tym tygodniu
Brak jeszcze wiadomości ze strony spółki.
Najwięksi akcjonariusze
| Posiadacz | Udział | Akcje | Data raportu |
|---|---|---|---|
| MPM Bioimpact LLC | 5.83% | 3.67 mln | 2026-06-30 |
| Siren, L.L.C. | 2.95% | 1.86 mln | 2026-06-30 |
| Vivo Capital, LLC | 2.93% | 1.84 mln | 2026-06-30 |
| Perceptive Advisors Llc | 2.63% | 1.65 mln | 2026-06-30 |
| Baker Bros. Advisors, LP | 2.32% | 1.46 mln | 2026-06-30 |
| Artisan Partners Limited… | 2.18% | 1.37 mln | 2026-06-30 |
| UBS Group AG | 2.09% | 1.31 mln | 2026-06-30 |
| Morgan Stanley | 1.52% | 954 908 | 2026-06-30 |
| Logos Global Management… | 1.46% | 915 000 | 2026-06-30 |
| Patient Square Capital L… | 1.45% | 909 474 | 2026-06-30 |
| Artisan Partners Funds I… | 1.34% | 840 251 | 2026-06-30 |
| Fidelity Advisor Series… | 0.68% | 428 800 | 2026-07-31 |
| iShares Trust-iShares Co… | 0.3% | 942 528 | 2026-08-31 |
| MOHIDEEN PHARIS (Officer… | ≈0.23% | 144 995 | 2026-01-29 |
| iShares Trust-iShares MS… | 0.21% | 666 480 | 2026-08-31 |
| Ikarian Capital, LLC | 0.19% | 525 000 | 2025-12-31 |
| RUSSELL INVESTMENT CO-Ta… | 0.07% | 45 089 | 2026-04-30 |
| College Retirement Equit… | 0.04% | 117 668 | 2026-06-30 |
| RUSSELL INVESTMENT CO-U.… | 0.04% | 22 707 | 2026-04-30 |
| Fidelity Salem Street Tr… | 0.03% | 108 080 | 2026-07-31 |
| SPDR INDEX SHARES Fd.S-S… | 0.03% | 105 233 | 2026-07-31 |
| Fidelity Concord Street… | 0.02% | 51 082 | 2026-07-31 |
| Fidelity Concord Street… | 0.02% | 12 855 | 2026-07-31 |
| iShares Trust-iShares Co… | 0.01% | 41 182 | 2026-08-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.01% | 36 650 | 2026-07-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.01% | 28 854 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.01% | 19 527 | 2026-08-31 |
| RUSSELL INVESTMENT FUNDS… | 0.01% | 5 834 | 2026-06-30 |
| Steward Funds Inc-Stewar… | 0.01% | 4 051 | 2026-04-30 |
| LORD ABBETT SECURITIES T… | 0% | 2 973 | 2026-04-30 |
| Trust for Professional M… | 0% | 2 245 | 2026-05-31 |
| Gabelli Healthcare & Wel… | 0% | 400 | 2026-06-30 |
